{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-173988","form_type":"8-K","ticker":"RPRX","cik":"0001802768","company_name":"Royalty Pharma plc","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.041651+00:00","generated_at":"2026-05-17T19:47:11.530441+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Royalty Pharma Q2 Portfolio Receipts +20% to $727M; raises FY 2025 guidance","bullets":["Portfolio Receipts $727M (+20% YoY); Royalty Receipts $672M (+11%), driven by Voranigo, Trelegy, Evrysdi, Tremfya.","Raised FY 2025 Portfolio Receipts guidance to $3.05B-$3.15B (was $2.975B-$3.125B).","Capital deployment of $595M in Q2; $1B in share repurchases in H1 2025 (31M shares).","Completed acquisition of external manager RP Management in May, making Royalty Pharma an integrated company.","Entered up to $2B funding arrangement with Revolution Medicines, including $1.25B synthetic royalty on daraxonrasib."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-173988","json":"https://secwatch.observer/filing/0001193125-25-173988.json","markdown":"https://secwatch.observer/filing/0001193125-25-173988.md","text":"https://secwatch.observer/filing/0001193125-25-173988.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802768/000119312525173988/0001193125-25-173988-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802768/000119312525173988/d90343d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T19:47:11.530441+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}